Cargando…
Re-definition of claudin-low as a breast cancer phenotype
The claudin-low breast cancer subtype is defined by gene expression characteristics and encompasses a remarkably diverse range of breast tumors. Here, we investigate genomic, transcriptomic, and clinical features of claudin-low breast tumors. We show that claudin-low is not simply a subtype analogou...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156396/ https://www.ncbi.nlm.nih.gov/pubmed/32286297 http://dx.doi.org/10.1038/s41467-020-15574-5 |
_version_ | 1783522197318402048 |
---|---|
author | Fougner, Christian Bergholtz, Helga Norum, Jens Henrik Sørlie, Therese |
author_facet | Fougner, Christian Bergholtz, Helga Norum, Jens Henrik Sørlie, Therese |
author_sort | Fougner, Christian |
collection | PubMed |
description | The claudin-low breast cancer subtype is defined by gene expression characteristics and encompasses a remarkably diverse range of breast tumors. Here, we investigate genomic, transcriptomic, and clinical features of claudin-low breast tumors. We show that claudin-low is not simply a subtype analogous to the intrinsic subtypes (basal-like, HER2-enriched, luminal A, luminal B and normal-like) as previously portrayed, but is a complex additional phenotype which may permeate breast tumors of various intrinsic subtypes. Claudin-low tumors are distinguished by low genomic instability, mutational burden and proliferation levels, and high levels of immune and stromal cell infiltration. In other aspects, claudin-low tumors reflect characteristics of their intrinsic subtype. Finally, we explore an alternative method for identifying claudin-low tumors and thereby uncover potential weaknesses in the established claudin-low classifier. In sum, these findings elucidate the heterogeneity in claudin-low breast tumors, and substantiate a re-definition of claudin-low as a cancer phenotype. |
format | Online Article Text |
id | pubmed-7156396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71563962020-04-22 Re-definition of claudin-low as a breast cancer phenotype Fougner, Christian Bergholtz, Helga Norum, Jens Henrik Sørlie, Therese Nat Commun Article The claudin-low breast cancer subtype is defined by gene expression characteristics and encompasses a remarkably diverse range of breast tumors. Here, we investigate genomic, transcriptomic, and clinical features of claudin-low breast tumors. We show that claudin-low is not simply a subtype analogous to the intrinsic subtypes (basal-like, HER2-enriched, luminal A, luminal B and normal-like) as previously portrayed, but is a complex additional phenotype which may permeate breast tumors of various intrinsic subtypes. Claudin-low tumors are distinguished by low genomic instability, mutational burden and proliferation levels, and high levels of immune and stromal cell infiltration. In other aspects, claudin-low tumors reflect characteristics of their intrinsic subtype. Finally, we explore an alternative method for identifying claudin-low tumors and thereby uncover potential weaknesses in the established claudin-low classifier. In sum, these findings elucidate the heterogeneity in claudin-low breast tumors, and substantiate a re-definition of claudin-low as a cancer phenotype. Nature Publishing Group UK 2020-04-14 /pmc/articles/PMC7156396/ /pubmed/32286297 http://dx.doi.org/10.1038/s41467-020-15574-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Fougner, Christian Bergholtz, Helga Norum, Jens Henrik Sørlie, Therese Re-definition of claudin-low as a breast cancer phenotype |
title | Re-definition of claudin-low as a breast cancer phenotype |
title_full | Re-definition of claudin-low as a breast cancer phenotype |
title_fullStr | Re-definition of claudin-low as a breast cancer phenotype |
title_full_unstemmed | Re-definition of claudin-low as a breast cancer phenotype |
title_short | Re-definition of claudin-low as a breast cancer phenotype |
title_sort | re-definition of claudin-low as a breast cancer phenotype |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156396/ https://www.ncbi.nlm.nih.gov/pubmed/32286297 http://dx.doi.org/10.1038/s41467-020-15574-5 |
work_keys_str_mv | AT fougnerchristian redefinitionofclaudinlowasabreastcancerphenotype AT bergholtzhelga redefinitionofclaudinlowasabreastcancerphenotype AT norumjenshenrik redefinitionofclaudinlowasabreastcancerphenotype AT sørlietherese redefinitionofclaudinlowasabreastcancerphenotype |